We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more capital invested

Capital invested by funds: $29.7M → $67.4M (+$37.8M)

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

7% more funds holding

Funds holding: 55 → 59 (+4)

4.82% more ownership

Funds ownership: 34.24% → 39.07% (+4.8%)

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
10
Reduced
18
Closed
11
Calls
$501K
Puts
–
Net Calls
+$501K
Net Calls Change
+$509K

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$5.99M
2
Jennison Associates
Jennison Associates
New York
+$3.53M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.07M
4
CAC
Cowen and Company
New York
+$1.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$464K

Top Sellers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
-$5.57M
2
BlackRock
BlackRock
New York
-$922K
3
SFM
Sphera Funds Management
Israel
-$763K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$469K
5
Renaissance Technologies
Renaissance Technologies
New York
-$257K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$15.8M +$168K +103,787 +2%
FCMI
2
Foresite Capital Management IV
California
$10.3M +$5.99M +3,705,128 New
Jennison Associates
3
Jennison Associates
New York
$8.18M +$3.53M +2,178,665 +285%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$5.27M +$3.07M +1,897,284 New
Morgan Stanley
5
Morgan Stanley
New York
$5.2M +$371K +229,442 +14%
LTFS
6
Ladenburg Thalmann Financial Services
Florida
$4.93M – – –
CAC
7
Cowen and Company
New York
$2.58M +$1.5M +926,200 New
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
$2.36M -$72.8K -45,000 -5%
Bank of Montreal
9
Bank of Montreal
Ontario, Canada
$1.99M -$469K -289,965 -29%
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.77M +$464K +286,577 +82%
Primecap Management
11
Primecap Management
California
$1.67M -$5.57M -3,440,900 -85%
Norges Bank
12
Norges Bank
Norway
$1.03M – – –
Millennium Management
13
Millennium Management
New York
$823K -$97.2K -60,090 -17%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$713K – – –
UBS Group
15
UBS Group
Switzerland
$676K +$92.4K +57,094 +31%
Verition Fund Management
16
Verition Fund Management
Connecticut
$485K +$282K +174,455 New
Qube Research & Technologies (QRT)
17
Qube Research & Technologies (QRT)
United Kingdom
$462K +$269K +166,138 New
CS
18
Credit Suisse
Switzerland
$403K +$235K +145,210 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$354K +$84.8K +52,387 +70%
BlackRock
20
BlackRock
New York
$274K -$922K -570,019 -85%
Two Sigma Investments
21
Two Sigma Investments
New York
$253K +$110K +68,265 +302%
Goldman Sachs
22
Goldman Sachs
New York
$239K -$29.3K -18,137 -17%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$225K +$2.75K +1,700 +2%
6CM
24
683 Capital Management
New York
$215K +$125K +77,368 New
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$179K +$82.9K +51,265 +395%
1
2 3

ABUS Hedge Fund Activity: Q4 2019 in Review

59 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2019, worth a combined $67.4M — up 127% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ABUS positions and 11 closed out — a net gain of 4 holders — while 10 added to existing stakes and 18 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $5.99M. The largest seller was Primecap Management, cutting an estimated $5.57M.

  • 59 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2019, up from 55 in Q3 2019.
  • Funds reported $67.4M of Arbutus Biopharma stock for Q4 2019, up 127% quarter-over-quarter.
  • 15 funds opened new Arbutus Biopharma positions in Q4 2019 and 11 closed out, a net change of +4 holders.
  • The largest Arbutus Biopharma buyer in Q4 2019 was Foresite Capital Management IV, an estimated $5.99M added.
  • The largest Arbutus Biopharma seller in Q4 2019 was Primecap Management, an estimated $5.57M sold.

Based on aggregated 13F filings for Q4 2019.